Department of War Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program
Key Dates
Due Date
-
Posted Date
-
Agency & Value
Agency
DEFENSE HEALTH AGENCY
Contract Value
Not provided
Codes & Classification
Solicitation Number
HT9402-26-Q-9401
NAICS
325412 - Pharmaceutical Preparation Manufacturing
Classification Code
6505
Additional Details
Documents5
The Department of Defense, through the Defense Health Agency (DHA), has issued a solicitation (Procurement Identifier: HT9402-26-Q-9401) for the establishment of Uniform Formulary Blanket Purchase Agreements (UF BPA) and Uniform Formulary Additional Discount Program Agreements (UF ADP) as part of its ongoing efforts to maintain an effective, efficient, and integrated pharmacy benefits program for the Military Health System (MHS). This initiative is mandated by 10 U.S.C. § 1074g and further guided by implementing regulations (32 CFR Section 199.21), which require the DHA Pharmacy and Therapeutics (P&T) Committee to evaluate pharmaceutical agents based on their clinical and cost effectiveness within specific therapeutic classes.
The primary purpose of this procurement is to secure competitive quotations from industry for pharmaceutical agents identified for potential inclusion in the DoD Uniform Formulary (UF). The UF serves as the basis for cost sharing and classification of pharmaceutical agents as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). The outcome of this process will directly influence the selection and pricing of drugs available to beneficiaries of the MHS.
For the November 2026 P&T Committee meeting, the following drug classes and subclasses are scheduled for review:
a. Atopy - Topical Agents:
- Anzupgo
- Eucrisa
- Opzelura
- Vtama
- Zoryve
b. Lung Cancer - METEX14:
- Tabrecta
- Tepmetko
Interested contractors are invited to review the attached Request for Quotation (RFQ), which includes detailed instructions, UF BPA and UF ADP appendices, important deadlines, and points of contact. A pre-quotation teleconference is scheduled for August 12, 2026, with further details provided in Part 2.4 of the RFQ. The solicitation is classified under NAICS Code 325412 (Pharmaceutical Preparation Manufacturing, 2022 version) and Product Service Code 6505, with the place of performance designated as Texas, United States.
The contracting entity is the Defense Health Agency, a federal office under the Department of Defense. Primary and secondary points of contact for this opportunity are Julia Trang ([email protected]) and Stephanie Erpelding ([email protected]), respectively.
This solicitation is active and accessible via SAM.gov (Opportunity ID: 36c934ac449246cb9565126a28c8d0f5), with a response deadline of January 10, 2026, at 17:10. Contractors specializing in pharmaceutical preparation manufacturing and possessing relevant products within the specified drug classes are encouraged to evaluate this opportunity for alignment with their capabilities. The procurement process, as outlined, will remain consistent throughout the contract lifecycle, focusing on the integration of clinically and cost-effective pharmaceutical agents into the DoD Uniform Formulary to support the health needs of military personnel and their families.